Inhibition of c-myc expression in cells by targeting an RNA-protein interaction using antisense oligonucleotides

Molecular Pharmacology

Volumn 57, Issue 3, 2000, Pages 485-494

  Coulis, Christopher M ^a   Lee, Chunja ^a   Nardone, Violet ^a   Prokipcak, Rebecca D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BINDING PROTEIN; MESSENGER RNA;

ARTICLE; CELL STRAIN K 562; CONCENTRATION RESPONSE; CONTROLLED STUDY; ERYTHROLEUKEMIA CELL; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA BINDING;

EID: 0034090251     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.57.3.485     Document Type: Article

References (44)

1. Andreou ER and Prokipcak RD (1998) Analysis of human CYP7A1 mRNA decay in HepG2 cells by reverse-transcription polymerase chain reaction. Arch Biochem Biophys 357:137-146.
2. Bacon TA and Wickstrom E (1991) Walking along human c-myc mRNA with antisense oligodeoxynucleotides: Maximum efficacy at the 5′ cap region. Oncogene Res 6:13-19.
3. Baker BF, Lot SS, Condon TP, Cheng-Flournoy S, Lesnik EA, Sasmor HM and Bennett CF (1997) 2′-O-(2-Methoxylethyl-modified anti-intracellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA levels and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem 272:11994-12000.
4. Bennett CF (1998) Antisense oligonucleotides: Is the glass half full or half empty? Bioehem Pharmacol 55:9-19.
5. Bernstein P, Herrick DJ, Prokipcak RD and Ross J (1992) Control of c-myc mRNA half-life in vitro by a protein capable of binding to a coding region stability determinant. Genes Deo 6:642-654.
6. Brewer G and Ross J (1989) Regulation of c-myc mRNA stability in vitro by a labile destabilizer with an essential nucleic acid component. Mol Cell Biol 9:1996-2006.
7. Calabretta B, Skorski T, Ratajczak MZ and Gewirtz AM (1996) Antisense strategies in the treatment of leukemias. Semin Oncol 23:78-87.
8. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res 47:936-942.
9. Chavany C, Connell Y and Neckers L (1995) Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers. Mol Pharmacol 48:738-746.
10. Chiang M-Y, Chan H, Zounes MA, Freier SM, Lima WF and Bennett CF (1991) Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem 266:18162-18171.
11. Citro G, D'Agnano I, Leonetti C, Perini R, Bucci B, Zon G, Calabretta B and Zupi G (1998) c-myc Antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res 58:283-289.
12. Cole MD (1986) The myc oncogene: Its role in transformation and differentiation. Anna Rev Genet 20:361-384.
13. Crooke ST (1993) Progress toward oligonucleotide therapeutics: Pharmacodynamic properties. FASEB J 7:533-539.
14. Deshler JO, Highett MI, Abramson T and Schnapp BJ (1998) A highly conserved RNA-binding protein for cytoplasmic mRNA localization in vertebrates. Curr Biol 8:489-496.
15. Doyle GAR, Betz NA, Leeds PF, Fleisig AJ, Prokipcak RD and Ross J (1998) The c-myc coding region determinant-binding protein: A member of a family of KH domain RNA-binding proteins. Nucleic Acids Res 26:5036-5044.
16. Field JK and Spandidos DA (1990) The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis (Review). Anticancer Res 10:1-22.
17. Gewirtz AM, Sokol DL and Ratajczak MZ (1998) Nucleic acid therapeutics: State of the art and future prospects. Blood 92:712-736.
18. Gryaznov S, Skorski T, Cucco C, Nieborowska-Skorska M, Chiu CY, Lloyd D, Chen J-K, Koziolkiewicz M and Calabretta B (1996) Oligonucleotide N3′-P5′ phosphoramidates as antisense agents. Nucleic Acids Res 24:1508-1514.
19. Havin L, Git A, Elisha Z, Oberman F, Yaniv K, Schwartz SP, Standart N and Yisraeli JK (1998) RNA-binding protein conserved in both microtubule-and microfilament-based RNA localization. Genes Dev 12:1593-1598.
20. Herrick DJ and Ross J (1994) The half-life of c-myc mRNA in growing and serum-stimulated cells: Influence of the coding and 3′ untranslated regions and role of ribosome translocation. Mol Cell Biol 14:2119-2128.
21. Khaled Z, Benimetskaya L, Zeltser R, Khan T, Sharma HW, Narayanan R and Stein CA (1996) Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 24:737-745.
22. Kimura S, Maekawa T, Hirakawa K, Murakami A and Abe T (1995) Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res 55:1379-1384.
23. Kislauskis EH, Zhu X and Singer RH (1994) Sequences responsible for intracellular localization of β-actin messenger RNA also affect cell phenotype. J Cell Biol 127:441-451.
24. Lee CH, Leeds P and Ross J (1998) Purification and characterization of a polysome-associated endoribonuclease that degrades c-myc mRNA in vitro. J Biol Chem 273:25261-25271.
25. Leeds P, Kren BT, Boylan JM, Betz NA, Steer CJ, Gruppuso PA and Ross J (1997) Developmental regulation of CRD-BP, an RNA-binding protein that stabilizes c-myc mRNA in vitro. Oncogene 14:1279-1286.
26. Leonetti C, D'Agnano I, Lozupone F, Valentini A, Geiser T, Zon G, Calabretta B, Citro G and Zupi G (1996) Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J Natl Cancer Inst 88:419-429.
27. McCarthy JEG and Kollmus H (1995) Cytoplasmic mRNA-protein interactions in eukaryotic gene expression. Trends Biochem Sci 20:191-197.
28. Monia BP, Lesnick EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, Kawasaki AM, Cook PD and Freier SM (1993) Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268:14514-14522.
29. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM and Nielsen FC (1999) A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 19:1262-1270.
30. Politz JC, Taneja KL and Singer RH (1995) Characterization of hybridization between synthetic oligodeoxynucleotides and RNA in living cells. Nucleic Acids Res 23:4946-4953.
31. Prokipcak RD, Herrick DJ and Ross J (1994) Purification and properties of a protein that binds to the C-terminal coding region of human c-myc mRNA. J Biol Chem 269:9261-9269.
32. Ratajczak MZ, Kant JA, Luger SM, Hijiya N, Zhang J, Zon G and Gewirtz AM (1992) In vivo treatment of human leukemia in an seid mouse model with c-myb antisense oligonucleotides. Proc Natl Acad Sci USA 89:11823-11827.
33. Ross AF, Oleynikov Y, Kislauskis EH, Taneja KL and Singer RH (1997) Characterization of a β-actin mRNA zip code-binding protein. Mol Cell Biol 17:2158-2165.
34. Ross J (1995) mRNA stability in mammalian cells. Microbiol Rev 59:423-450.
35. Ross J, Kobs G, Brewer G and Peltz SW (1987) Properties of the exonuclease activity that degrades H4 histone mRNA. J Biol Chem 262:9374-9381.
36. Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, lozzo RV and Calabretta B (1996) Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Blood 88:1005-1012.
37. Skorski T, Perrotti D, Nieborowska-Skorski M, Gryaznov S and Calabretta B (1997) Antileukemia effect of c-myc N3′-P5′ phosphoroamidate antisense oligonucleotides in vivo. Proc Natl Acad Sci USA 94:3966-3971.
38. Stein CA (1995) Does antisense exist? Nat Med 1:1119-1121.
39. Stein CA and Cheng Y-C (1993) Antisense oligonucleotides as therapeutic agents: Is the bullet really magical? Science (Wash DC) 261:1004-1012.
40. Tu G-C, Cao Q-N, Zhou F and Israel Y (1998) Tetranucleotide GGGA motif primary RNA transcripts: Novel target site for antisense design. J Biol Chem 273:25125-26131.
41. Wagner RW (1994) Gene inhibition using antisense oligodeoxynucleotides. Nature (Lond) 372:333-335.
42. Watson PH, Pon RT and Shiu RPC (1991) Inhibition of c-myc expression by phos-phorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 51:3996-4000.
43. Wisdom R and Lee W (1991) The protein-coding region of c-myc mRNA contains a sequence that specifies rapid mRNA turnover and induction by protein synthesis inhibitors. Genes Dev 5:232-243.
44. Zhang W, Wagner BJ, Ehrenman K, Schaefer AW, DeMaria CT, Crater D, DeHaven K, Long L and Brewer G (1993) Purification, characterization, and cDNA cloning of an AU-rich element RNA-binding protein, AUF1. Mol Cell Biol 13:7652-7665.